These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27890820)

  • 1. Recent developments in natural product-based drug discovery for tuberculosis.
    Dong M; Pfeiffer B; Altmann KH
    Drug Discov Today; 2017 Mar; 22(3):585-591. PubMed ID: 27890820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents.
    Farah SI; Abdelrahman AA; North EJ; Chauhan H
    Assay Drug Dev Technol; 2016; 14(1):29-38. PubMed ID: 26565779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives on natural products in TB drug research.
    Pauli GF; Case RJ; Inui T; Wang Y; Cho S; Fischer NH; Franzblau SG
    Life Sci; 2005 Dec; 78(5):485-94. PubMed ID: 16243360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery.
    Cazzaniga G; Mori M; Chiarelli LR; Gelain A; Meneghetti F; Villa S
    Eur J Med Chem; 2021 Nov; 224():113732. PubMed ID: 34399099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and revisited approaches in antituberculosis drug discovery.
    Herrmann J; Rybniker J; Müller R
    Curr Opin Biotechnol; 2017 Dec; 48():94-101. PubMed ID: 28427007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current perspectives in drug discovery against tuberculosis from natural products.
    Nguta JM; Appiah-Opong R; Nyarko AK; Yeboah-Manu D; Addo PG
    Int J Mycobacteriol; 2015 Sep; 4(3):165-83. PubMed ID: 27649863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenolic Compounds as Promising Drug Candidates in Tuberculosis Therapy.
    Mazlun MH; Sabran SF; Mohamed M; Abu Bakar MF; Abdullah Z
    Molecules; 2019 Jul; 24(13):. PubMed ID: 31277371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recently disclosed chemical entities as potential candidates for management of tuberculosis.
    Stec J; Abourashed EA
    Pharm Pat Anal; 2015; 4(4):317-47. PubMed ID: 26174569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update.
    Kumar G; C A
    Drug Dev Res; 2023 Aug; 84(5):779-804. PubMed ID: 37086027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.
    Ntie-Kang F; Yong JN; Owono Owono LC; Sippl W; Megnassan E
    Curr Med Chem; 2014; 21(30):3466-77. PubMed ID: 25005178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model to predict anti-tuberculosis activity: value proposition for marine microorganisms.
    Liu M; Grkovic T; Zhang L; Liu X; Quinn RJ
    J Antibiot (Tokyo); 2016 Aug; 69(8):594-9. PubMed ID: 27406906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tuberculosis drug discovery and development pipeline and emerging drug targets.
    Mdluli K; Kaneko T; Upton A
    Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25635061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the tuberculosis drug development pipeline.
    Evangelopoulos D; McHugh TD
    Chem Biol Drug Des; 2015 Nov; 86(5):951-60. PubMed ID: 25772393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-mycobacterial natural products and mechanisms of action.
    Han J; Liu X; Zhang L; Quinn RJ; Feng Y
    Nat Prod Rep; 2022 Jan; 39(1):77-89. PubMed ID: 34226909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
    De Leon Rodriguez LM; Kaur H; Brimble MA
    Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TB drug development: immunology at the table.
    Nathan C; Barry CE
    Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compelling Cyclic Peptide Scaffolds for Antitubercular Action: An Account (2011-21) of the Natural Source.
    Chowdhury A; Bandyopadhyay A
    Curr Protein Pept Sci; 2022; 23(12):823-836. PubMed ID: 36200246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Natural Product That Binds to the
    Elnaas AR; Grice D; Han J; Feng Y; Capua AD; Mak T; Laureanti JA; Buchko GW; Myler PJ; Cook G; Quinn RJ; Liu M
    Molecules; 2020 May; 25(10):. PubMed ID: 32455540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.